| Membrane transporters in drug development KM Giacomini, SM Huang, DJ Tweedie, LZ Benet, KLR Brouwer, X Chu, ... Nature reviews Drug discovery 9 (3), 215, 2010 | 3484* | 2010 |
| Drug interactions with lipid‐lowering drugs: mechanisms and clinical relevance PJ Neuvonen, M Niemi, JT Backman Clinical Pharmacology & Therapeutics 80 (6), 565-581, 2006 | 1051 | 2006 |
| Impact of OATP transporters on pharmacokinetics A Kalliokoski, M Niemi British journal of pharmacology 158 (3), 693-705, 2009 | 1043 | 2009 |
| Pharmacokinetic interactions with rifampicin: clinical relevance M Niemi, JT Backman, MF Fromm, PJ Neuvonen, KT Kivistö Clinical pharmacokinetics 42, 819-850, 2003 | 862 | 2003 |
| Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake M Niemi, MK Pasanen, PJ Neuvonen Pharmacological reviews 63 (1), 157-181, 2011 | 699 | 2011 |
| SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid MK Pasanen, M Neuvonen, PJ Neuvonen, M Niemi Pharmacogenetics and genomics 16 (12), 873-879, 2006 | 586 | 2006 |
| Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin MK Pasanen, H Fredrikson, PJ Neuvonen, M Niemi Clinical Pharmacology & Therapeutics 82 (6), 726-733, 2007 | 517 | 2007 |
| High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1) M Niemi, E Schaeffeler, T Lang, MF Fromm, M Neuvonen, C Kyrklund, ... Pharmacogenetics and Genomics 14 (7), 429-440, 2004 | 510 | 2004 |
| The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin‐Induced Myopathy: 2014 Update LB Ramsey, SG Johnson, KE Caudle, CE Haidar, D Voora, RA Wilke, ... Clinical Pharmacology & Therapeutics 96 (4), 423-428, 2014 | 456 | 2014 |
| ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin JE Keskitalo, O Zolk, MF Fromm, KJ Kurkinen, PJ Neuvonen, M Niemi Clinical Pharmacology & Therapeutics 86 (2), 197-203, 2009 | 446 | 2009 |
| Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics M Niemi, JT Backman, LI Kajosaari, JB Leathart, M Neuvonen, AK Daly, ... Clinical Pharmacology & Therapeutics 77 (6), 468-478, 2005 | 431 | 2005 |
| The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin‐Induced Myopathy RA Wilke, LB Ramsey, SG Johnson, WD Maxwell, HL McLeod, D Voora, ... Clinical Pharmacology & Therapeutics 92 (1), 112-117, 2012 | 360 | 2012 |
| Transporter pharmacogenetics and statin toxicity M Niemi Clinical Pharmacology & Therapeutics 87 (1), 130-133, 2010 | 357 | 2010 |
| Role of OATP transporters in the disposition of drugs M Niemi Future Medicine Ltd 8 (7), 787-802, 2007 | 333 | 2007 |
| Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil … M Niemi, JT Backman, M Neuvonen, PJ Neuvonen Diabetologia 46, 347-351, 2003 | 319 | 2003 |
| SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin M Niemi, MK Pasanen, PJ Neuvonen Clinical Pharmacology & Therapeutics 80 (4), 356-366, 2006 | 294 | 2006 |
| Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin PJ Neuvonen, JT Backman, M Niemi Clinical pharmacokinetics 47, 463-474, 2008 | 273 | 2008 |
| Gemfibrozil considerably increases the plasma concentrations of rosiglitazone M Niemi, JT Backman, M Granfors, J Laitila, M Neuvonen, PJ Neuvonen Diabetologia 46, 1319-1323, 2003 | 253 | 2003 |
| Cyclosporine markedly raises the plasma concentrations of repaglinide LI Kajosaari, M Niemi, M Neuvonen, J Laitila, PJ Neuvonen, JT Backman Clinical Pharmacology & Therapeutics 78 (4), 388-399, 2005 | 252 | 2005 |
| Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes M Niemi, I Cascorbi, R Timm, HK Kroemer, PJ Neuvonen, KT Kivistö Clinical Pharmacology & Therapeutics 72 (3), 326-332, 2002 | 235 | 2002 |
